Barinthus Biotherapeutics (BRNS) Total Debt (2021)

Barinthus Biotherapeutics (BRNS) reported Total Debt of $159000.0 for Q4 2021.

Barinthus Biotherapeutics (BRNS) Total Debt (2021) Analysis & Trends

Barinthus Biotherapeutics has reported Total Debt for 1 years, with the latest figure at $159000.0 in Q4 2021.

  • For the quarter ending Q4 2021, Total Debt changed N/A year-over-year to $159000.0; the trailing twelve-month figure through Dec 2021 stood at $159000.0 (changed N/A YoY), and the FY2021 full-year result was $159000.0, changed N/A from the prior year.
  • Total Debt for Q4 2021 stood at $159000.0.
  • The five-year high for Total Debt was $159000.0 in Q4 2021, with the low at $159000.0 in Q4 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Alterity Therapeutics 719,706.53 Bn 719,706.50 Bn - -
2 Belite Bio 55,800.00 Bn 55,800.00 Bn - -
3 Quantum Biopharma 18,182.30 Bn 18,182.29 Bn - -
4 Legend Biotech 3,154.00 Bn 3,153.71 Bn 242.10 Mn 319.10 Mn
5 Akari Therapeutics 1,844.30 Bn 1,844.29 Bn - -
6 Evaxion A 1,567.96 Bn 1,567.94 Bn - -
7 Psyence Biomedical 251.43 Bn 251.42 Bn - -
8 Vertex Pharmaceuticals 112.56 Bn 105.31 Bn 2.59 Bn -
9 Abivax 94.37 Bn 94.37 Bn - -
10 Barinthus Biotherapeutics 27.08 Mn -40.03 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2021 159,000.00